Key result
High depressive symptoms linked to ~75% lower rate of SDAI remission.
Why the study?
Do depressive symptoms predict future disease activity and remission in patients with early inflammatory polyarthritis?
Cohort (n=275)
Do depressive symptoms predict future disease activity and remission in patients with early inflammatory polyarthritis?
Depressive symptoms at 12 months in treated early inflammatory polyarthritis patients strongly predict delayed and failed disease remission.
Depressive symptoms may track with SDAI in treated EPA; leaves open causality and whether screening alters outcomes.
OBJECTIVE: To determine whether depressive symptoms assessed in treated patients with early inflammatory polyarthritis (EPA) influence disease activity during follow-up. METHODS: Consecutively recruited EPA patients were actively treated to remission. Simple disease activity index (SDAI) and Center for Epidemiologic Studies Depression Scale (CES-D) scores were calculated at inclusion and up to 42 months into disease. SDAI scores were log-transformed to compute univariate and multivariate linear regressions. Parametric interval-censored Kaplan-Meier and survival regressions using Weibull distribution were used to assess time to and predictors of SDAI remission. RESULTS: A total of 275 EPA patients were recruited at a median of 4 months into disease. In multivariate linear regression models, accounting for baseline demographic, clinical, serological and functional variables and 12-month inflammation markers, CES-D scores at 12 months into disease were correlated (r(2) = 0.14) with subsequent SDAI scores. Patients with 12-month high CES-D (≥19; suggestive of depression) had a lower proportion of SDAI remission (31.3% vs 84.3%; P < 0.001) and reached SDAI remission less rapidly [hazard ratio = 0.25 (95% CI 0.12, 0.53); P < 0.001]. CONCLUSION: Each follow-up SDAI correlated significantly with 12-month depressive symptoms, a median of 7 months after initiation of treatment. CES-D scores suggestive of depression at 12 months were strongly correlated with delay and failure to reach remission later on. Depressive symptoms in treated EPA patients represent important clinical issues with long-term association with disease activity. Interventions to alleviate persistent depressive symptoms in treated EPA warrant careful evaluation of their potential to improve disease remission rates.
No takes yet. Share an insight, caveat, or question.
Leblanc-Trudeau et al. (2015) conducted a cohort in Early inflammatory polyarthritis (n=275). High depressive symptoms (CES-D score ≥19) vs. Low depressive symptoms (CES-D score <19) was evaluated on SDAI remission (HR 0.25, 95% CI 0.12, 0.53, p=< 0.001). High depressive symptoms at 12 months were associated with a lower rate of SDAI remission compared to those without high symptoms (31.3% vs 84.3%; HR 0.25; 95% CI 0.12-0.53; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: